[
  {
    "ts": "2025-08-05T21:15:53+00:00",
    "headline": "Stocks to Watch Recap: Palantir, Coinbase, Gartner, Pfizer",
    "summary": "↗️ Palantir (PLTR): Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and boosted its annual outlook. ↘️Coinbase Global (COIN): Shares in the cryptocurrency exchange dropped 6.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-08-05-2025/card/stocks-to-watch-tuesday-palantir-bp-pfizer-zvFbX1RyaOLQhZPJQBNV?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "ece15fb9-9c8f-3367-92c6-c6f750227961",
      "content": {
        "id": "ece15fb9-9c8f-3367-92c6-c6f750227961",
        "contentType": "STORY",
        "title": "Stocks to Watch Recap: Palantir, Coinbase, Gartner, Pfizer",
        "description": "",
        "summary": "↗️ Palantir (PLTR): Shares in the data-software company were up 7.8% Tuesday after it posted higher quarterly results and boosted its annual outlook. ↘️Coinbase Global (COIN): Shares in the cryptocurrency exchange dropped 6.",
        "pubDate": "2025-08-05T21:15:53Z",
        "displayTime": "2025-08-05T21:15:53Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ece15fb9-9c8f-3367-92c6-c6f750227961/stocks-to-watch-recap-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/7488784e51c674d436efe2e1d40a464f",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ZJDdvCt5.o0aGefVXJ5SxA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/7488784e51c674d436efe2e1d40a464f.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ijybTjOhG7GUb7vNhDFAGQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/7488784e51c674d436efe2e1d40a464f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-08-05-2025/card/stocks-to-watch-tuesday-palantir-bp-pfizer-zvFbX1RyaOLQhZPJQBNV?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IT"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "COIN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "AXON"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T20:44:00+00:00",
    "headline": "These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More",
    "summary": "Palantir rose after earnings blew past Wall Street estimates. Shares of Vertex Pharmaceuticals and Hims & Hers plummeted on weak quarterly results.",
    "url": "https://www.barrons.com/articles/stock-movers-3ba2a1af?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "3e1f1608-d676-33a1-aa1c-2de47ca03925",
      "content": {
        "id": "3e1f1608-d676-33a1-aa1c-2de47ca03925",
        "contentType": "STORY",
        "title": "These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More",
        "description": "",
        "summary": "Palantir rose after earnings blew past Wall Street estimates. Shares of Vertex Pharmaceuticals and Hims & Hers plummeted on weak quarterly results.",
        "pubDate": "2025-08-05T20:44:00Z",
        "displayTime": "2025-08-05T20:44:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/3e1f1608-d676-33a1-aa1c-2de47ca03925/these-stocks-moved-the-most.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/3a59fef615d05dadb9f2ce0759a37de6",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2OcOZ3Xw7DxGST7XLvUPXA--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/3a59fef615d05dadb9f2ce0759a37de6.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pM7.xUbY_WuqIkIKkseV8A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/3a59fef615d05dadb9f2ce0759a37de6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/stock-movers-3ba2a1af?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "HIMS"
            },
            {
              "symbol": "COIN"
            },
            {
              "symbol": "BP.L"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T20:20:21+00:00",
    "headline": "Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat",
    "summary": "Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into additional testing.",
    "url": "https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q2-2025/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "49202aed-b4db-36a8-aa03-9dab60026ded",
      "content": {
        "id": "49202aed-b4db-36a8-aa03-9dab60026ded",
        "contentType": "STORY",
        "title": "Why Vertex Pharma Is Feeling The Pain Despite A Second-Quarter Beat",
        "description": "",
        "summary": "Vertex stock nose-dived Tuesday after the biotech company said it wouldn't advance its next-generation pain drug into additional testing.",
        "pubDate": "2025-08-05T20:20:21Z",
        "displayTime": "2025-08-05T20:20:21Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/49202aed-b4db-36a8-aa03-9dab60026ded/why-vertex-pharma-is-feeling.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/fd88dd49a5bbb14fdbe73fa70a0a571c",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/29Nvl3QFHIYUC2bvA1LGaA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/fd88dd49a5bbb14fdbe73fa70a0a571c.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/0POtGNtIrqoEzdTvVpzFzQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/fd88dd49a5bbb14fdbe73fa70a0a571c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/vertex-stock-vertex-pharmaceuticals-earnings-q2-2025/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T19:50:50+00:00",
    "headline": "Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today",
    "summary": "Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial. The company’s experimental non-opioid painkiller, VX-993, failed to achieve a statistically significant pain reduction compared to a placebo in a mid-stage study. The trial involved patients who had undergone bunionectomy surgery. Following the failure, Vertex Pharmaceuticals stated it would stop",
    "url": "https://finance.yahoo.com/news/why-vertex-pharmaceuticals-vrtx-stock-195050135.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "602a1432-ed8f-3f09-8647-6645de83bfcd",
      "content": {
        "id": "602a1432-ed8f-3f09-8647-6645de83bfcd",
        "contentType": "STORY",
        "title": "Why Vertex Pharmaceuticals (VRTX) Stock Is Trading Lower Today",
        "description": "",
        "summary": "Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial. The company’s experimental non-opioid painkiller, VX-993, failed to achieve a statistically significant pain reduction compared to a placebo in a mid-stage study. The trial involved patients who had undergone bunionectomy surgery. Following the failure, Vertex Pharmaceuticals stated it would stop",
        "pubDate": "2025-08-05T19:50:50Z",
        "displayTime": "2025-08-05T19:50:50Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "VRTX Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/l6Y31wu10RiElUns.3mORA--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qe_uhCRKlCGgByoENi3GZg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/deb3d79d2e2c41377b0b2ebb8ef2e4cd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/why-vertex-pharmaceuticals-vrtx-stock-195050135.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-vertex-pharmaceuticals-vrtx-stock-195050135.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T17:00:08+00:00",
    "headline": "VRTX: Vertex Shares Tank After Pain Drug Flop in Key Trial",
    "summary": "Vertex stock drops sharply after its pain drug fails a crucial clinical trial.",
    "url": "https://finance.yahoo.com/news/vrtx-vertex-shares-tank-pain-162727736.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "5ac06a3a-b266-3dda-8342-226480c65e2c",
      "content": {
        "id": "5ac06a3a-b266-3dda-8342-226480c65e2c",
        "contentType": "STORY",
        "title": "VRTX: Vertex Shares Tank After Pain Drug Flop in Key Trial",
        "description": "",
        "summary": "Vertex stock drops sharply after its pain drug fails a crucial clinical trial.",
        "pubDate": "2025-08-05T17:00:08Z",
        "displayTime": "2025-08-05T17:00:08Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/9ad9baa872cd36658a2db63b8eb4608a",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yDsKaqARbNgha28_qyzHaQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/9ad9baa872cd36658a2db63b8eb4608a.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qO.qSuA3dSl8cTtC0M9sxQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/9ad9baa872cd36658a2db63b8eb4608a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vrtx-vertex-shares-tank-pain-162727736.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vrtx-vertex-shares-tank-pain-162727736.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T15:54:00+00:00",
    "headline": "CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption",
    "summary": "CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.",
    "url": "https://finance.yahoo.com/news/crsp-stock-down-huge-q2-155400470.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "e785abec-4978-3c09-9988-638536a8458a",
      "content": {
        "id": "e785abec-4978-3c09-9988-638536a8458a",
        "contentType": "STORY",
        "title": "CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption",
        "description": "",
        "summary": "CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.",
        "pubDate": "2025-08-05T15:54:00Z",
        "displayTime": "2025-08-05T15:54:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/crsp-stock-down-huge-q2-155400470.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/crsp-stock-down-huge-q2-155400470.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CRSP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T15:38:55+00:00",
    "headline": "Top Stock Movers Now: Gartner, Axon Enterprise, Palantir, and More",
    "summary": "U.S. equities declined at midday following a soft services industry report and President Donald Trump's comments on new tariffs.",
    "url": "https://www.investopedia.com/top-stock-movers-now-gartner-axon-enterprise-palantir-and-more-11785000",
    "source": "Investopedia",
    "provider": "yfinance",
    "raw": {
      "id": "44fde8b8-4089-3c7b-b628-a5ec84929d4e",
      "content": {
        "id": "44fde8b8-4089-3c7b-b628-a5ec84929d4e",
        "contentType": "STORY",
        "title": "Top Stock Movers Now: Gartner, Axon Enterprise, Palantir, and More",
        "description": "",
        "summary": "U.S. equities declined at midday following a soft services industry report and President Donald Trump's comments on new tariffs.",
        "pubDate": "2025-08-05T15:38:55Z",
        "displayTime": "2025-08-05T15:38:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/investopedia_245/341bbdfc9d6a87d356296c4d235f6f65",
          "originalWidth": 6240,
          "originalHeight": 4160,
          "caption": "Jaque Silva / NurPhoto via Getty Images Gartner was the worst-performing stock in the S&P 500 when the research and advisory firm slashed its guidance on declining revenue at its largest research unit",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ENpPzkIRYiWvnlIo2HDHzw--~B/aD00MTYwO3c9NjI0MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/investopedia_245/341bbdfc9d6a87d356296c4d235f6f65.cf.webp",
              "width": 6240,
              "height": 4160,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Id4Kzd7LRIJG2gkknXCOXQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investopedia_245/341bbdfc9d6a87d356296c4d235f6f65.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investopedia",
          "url": "https://www.investopedia.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investopedia.com/top-stock-movers-now-gartner-axon-enterprise-palantir-and-more-11785000",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-stock-movers-now-gartner-153855996.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AXON"
            },
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "DD"
            },
            {
              "symbol": "^DJI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T15:33:00+00:00",
    "headline": "VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal",
    "summary": "Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.",
    "url": "https://finance.yahoo.com/news/vrtx-q2-earnings-beat-stock-153300623.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "cbbf5e6d-ca32-3eb1-ab7b-87860ed110b8",
      "content": {
        "id": "cbbf5e6d-ca32-3eb1-ab7b-87860ed110b8",
        "contentType": "STORY",
        "title": "VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal",
        "description": "",
        "summary": "Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.",
        "pubDate": "2025-08-05T15:33:00Z",
        "displayTime": "2025-08-05T15:33:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/clkf5pUY76l.nElrYS4s6w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Fd4LKz3FaED4STL9jWy9kw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/5c26ab1f8b890434759145296588998c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vrtx-q2-earnings-beat-stock-153300623.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vrtx-q2-earnings-beat-stock-153300623.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T14:12:00+00:00",
    "headline": "Vertex Stock Tumbles After Strong Earnings. What’s Spooking Investors.",
    "summary": "Second-quarter adjusted earnings came in at $4.52 a share on revenue of $2.96 billion, beating expectations.",
    "url": "https://www.barrons.com/articles/vertex-earnings-stock-price-drug-b7870a66?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "ec28e4af-7a6c-36cd-be33-ca3e02cfa348",
      "content": {
        "id": "ec28e4af-7a6c-36cd-be33-ca3e02cfa348",
        "contentType": "STORY",
        "title": "Vertex Stock Tumbles After Strong Earnings. What’s Spooking Investors.",
        "description": "",
        "summary": "Second-quarter adjusted earnings came in at $4.52 a share on revenue of $2.96 billion, beating expectations.",
        "pubDate": "2025-08-05T14:12:00Z",
        "displayTime": "2025-08-05T14:12:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ec28e4af-7a6c-36cd-be33-ca3e02cfa348/vertex-stock-tumbles-after.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/620a397460680a890d333b36e0ff82a8",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2CugfokEIfq4OCUxfvo8Rg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/620a397460680a890d333b36e0ff82a8.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/x3Elf7Wlb8cTJpjtDxtMRA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/620a397460680a890d333b36e0ff82a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/vertex-earnings-stock-price-drug-b7870a66?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T13:58:59+00:00",
    "headline": "Stocks See Support from Strong Earnings and Rate Cut Speculation",
    "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.20%. September E-mini S&P futures (ESU25 ) are up +0.15%, and September E-mini Nasdaq futures...",
    "url": "https://www.barchart.com/story/news/33889731/stocks-see-support-from-strong-earnings-and-rate-cut-speculation",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "469b072e-843c-3249-b1fe-58aa2561c364",
      "content": {
        "id": "469b072e-843c-3249-b1fe-58aa2561c364",
        "contentType": "STORY",
        "title": "Stocks See Support from Strong Earnings and Rate Cut Speculation",
        "description": "",
        "summary": "The S&P 500 Index ($SPX ) (SPY ) today is up +0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.24%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.20%. September E-mini S&P futures (ESU25 ) are up +0.15%, and September E-mini Nasdaq futures...",
        "pubDate": "2025-08-05T13:58:59Z",
        "displayTime": "2025-08-05T13:58:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/bc1ca70c2b48d920c5437c60396a6beb",
          "originalWidth": 1600,
          "originalHeight": 1067,
          "caption": "Wall street sign in New York City by f11photo via Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bwBebO3EKFrT3Bes6W10VQ--~B/aD0xMDY3O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/bc1ca70c2b48d920c5437c60396a6beb.cf.webp",
              "width": 1600,
              "height": 1067,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Y2rNe4o.0QrHkdYcWKlFog--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/bc1ca70c2b48d920c5437c60396a6beb.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/33889731/stocks-see-support-from-strong-earnings-and-rate-cut-speculation",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stocks-see-support-strong-earnings-135859709.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^NDX"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "PLTR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T13:52:29+00:00",
    "headline": "Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug",
    "summary": "Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.",
    "url": "https://www.investopedia.com/vertex-pharmaceutical-stock-dives-as-firm-to-stop-developing-acute-pain-drug-11784859",
    "source": "Investopedia",
    "provider": "yfinance",
    "raw": {
      "id": "2da37977-f3a8-3df7-b01e-5cfe53205b01",
      "content": {
        "id": "2da37977-f3a8-3df7-b01e-5cfe53205b01",
        "contentType": "STORY",
        "title": "Vertex Pharmaceutical Stock Dives as Firm to Stop Developing Acute Pain Drug",
        "description": "",
        "summary": "Shares of Vertex Pharmaceuticals sank 15% after the drugmaker announced a study showed its experimental pain medicine was not successful, and it would no longer move forward with its development.",
        "pubDate": "2025-08-05T13:52:29Z",
        "displayTime": "2025-08-05T13:52:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/investopedia_245/23fbd9964dd17c004c5c1ab2bd44d58c",
          "originalWidth": 6708,
          "originalHeight": 4472,
          "caption": "Cheng Xin / Getty Images Shares of Vertex Pharmaceuticals sank 15% soon after the opening bell Tuesday, Aug. 5, 2025",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hSCLBPDLjSGYDqBmCL9aww--~B/aD00NDcyO3c9NjcwODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/investopedia_245/23fbd9964dd17c004c5c1ab2bd44d58c.cf.webp",
              "width": 6708,
              "height": 4472,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5cZU84y9SZz2TvGqZmlLCg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investopedia_245/23fbd9964dd17c004c5c1ab2bd44d58c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investopedia",
          "url": "https://www.investopedia.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investopedia.com/vertex-pharmaceutical-stock-dives-as-firm-to-stop-developing-acute-pain-drug-11784859",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceutical-stock-dives-firm-135229123.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T13:41:30+00:00",
    "headline": "Vertex Pharmaceuticals, Kyndryl, Caterpillar: Trending Tickers",
    "summary": "Vertex Pharmaceuticals (VRTX) stock is sliding after the company said it won't advance its pain treatment into the next phase of testing. Kyndryl's (KD) consulting revenue jumped 30%. Caterpillar (CAT) missed profit estimates and warned about the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
    "url": "https://finance.yahoo.com/video/vertex-pharmaceuticals-kyndryl-caterpillar-trending-134130789.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "f86f16a6-2816-3c2a-be1c-342525b32a62",
      "content": {
        "id": "f86f16a6-2816-3c2a-be1c-342525b32a62",
        "contentType": "VIDEO",
        "title": "Vertex Pharmaceuticals, Kyndryl, Caterpillar: Trending Tickers",
        "description": "<p>Vertex Pharmaceuticals (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/VRTX\">VRTX</a>) stock is sliding after the company said it won't advance its pain treatment into the next phase of testing.</p>\n<p>Kyndryl's (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/KD\">KD</a>) consulting revenue jumped 30%.</p>\n<p>Caterpillar (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/CAT\">CAT</a>) missed profit estimates and warned about the impact of tariffs.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/videos/series/morning-brief/\">Morning Brief</a>.</p>",
        "summary": "Vertex Pharmaceuticals (VRTX) stock is sliding after the company said it won't advance its pain treatment into the next phase of testing. Kyndryl's (KD) consulting revenue jumped 30%. Caterpillar (CAT) missed profit estimates and warned about the impact of tariffs. To watch more expert insights and analysis on the latest market action, check out more&nbsp;Morning Brief.",
        "pubDate": "2025-08-05T13:41:30Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-08/31adb700-7200-11f0-a6fb-ede79a78e5f6",
          "originalWidth": 6708,
          "originalHeight": 3777,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yZ6u1bbRD_RBMX2M6oC_Rw--~B/aD0zNzc3O3c9NjcwODthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-08/31adb700-7200-11f0-a6fb-ede79a78e5f6.cf.webp",
              "width": 6708,
              "height": 3777,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9eXLnlpCXxcI1UQ0kiDjTg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-08/31adb700-7200-11f0-a6fb-ede79a78e5f6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/vertex-pharmaceuticals-kyndryl-caterpillar-trending-134130789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/vertex-pharmaceuticals-kyndryl-caterpillar-trending-134130789.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KD"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "CAT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T12:00:00+00:00",
    "headline": "Vortex Energy Mobilizes Field Crews for ANT Survey at Robinsons River Salt Project",
    "summary": "Field Crews Begin Deployment of Ant Sensors to Image Subsurface at Robinsons RiverVANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that field crews are mobilizing to the Robinsons River Salt Project in Newfoundland to initiate the deployment of Ambient Noise Tomography (“ANT”) sensors. This marks the start of the Company’s flagship geophysical survey designed to image the subs",
    "url": "https://finance.yahoo.com/news/vortex-energy-mobilizes-field-crews-120000626.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "ebaed0a0-555e-3eff-90e1-611c79c4af25",
      "content": {
        "id": "ebaed0a0-555e-3eff-90e1-611c79c4af25",
        "contentType": "STORY",
        "title": "Vortex Energy Mobilizes Field Crews for ANT Survey at Robinsons River Salt Project",
        "description": "",
        "summary": "Field Crews Begin Deployment of Ant Sensors to Image Subsurface at Robinsons RiverVANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Vortex Energy Corp. (CSE: VRTX) (OTC: VTECF) (FSE: AA3) (“Vortex” or the “Company”) is pleased to announce that field crews are mobilizing to the Robinsons River Salt Project in Newfoundland to initiate the deployment of Ambient Noise Tomography (“ANT”) sensors. This marks the start of the Company’s flagship geophysical survey designed to image the subs",
        "pubDate": "2025-08-05T12:00:00Z",
        "displayTime": "2025-08-05T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/513e0883ed6a478a2036119d3f0619da",
          "originalWidth": 1297,
          "originalHeight": 505,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tk46GwrdVa_eAkyzErR_YA--~B/aD01MDU7dz0xMjk3O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/513e0883ed6a478a2036119d3f0619da.cf.webp",
              "width": 1297,
              "height": 505,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5H.IMNgt5uPIavdTamohpQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/513e0883ed6a478a2036119d3f0619da.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vortex-energy-mobilizes-field-crews-120000626.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vortex-energy-mobilizes-field-crews-120000626.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VTECF"
            },
            {
              "symbol": "VRTX.CN"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "STRM.V"
            },
            {
              "symbol": "ENGT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T11:36:22+00:00",
    "headline": "5 Things to Know Before the Stock Market Opens",
    "summary": "News of the day for August 5, 2025",
    "url": "https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-august-05-2025-11784826",
    "source": "Investopedia",
    "provider": "yfinance",
    "raw": {
      "id": "001ed80d-3571-315c-9aee-8a449b911eb7",
      "content": {
        "id": "001ed80d-3571-315c-9aee-8a449b911eb7",
        "contentType": "STORY",
        "title": "5 Things to Know Before the Stock Market Opens",
        "description": "",
        "summary": "News of the day for August 5, 2025",
        "pubDate": "2025-08-05T11:36:22Z",
        "displayTime": "2025-08-05T11:36:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/investopedia_245/fa4aac6a7977de34ff348f5c74809027",
          "originalWidth": 7567,
          "originalHeight": 5045,
          "caption": "ANGELA WEISS / AFP via Getty Images U.S. stock futures are pointing higher Tuesday, Aug. 5, 2025",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Viat_cNvh0sR1WkbcNxVOg--~B/aD01MDQ1O3c9NzU2NzthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/investopedia_245/fa4aac6a7977de34ff348f5c74809027.cf.webp",
              "width": 7567,
              "height": 5045,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hkVF3QSp6CnSPnurQBqbiw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/investopedia_245/fa4aac6a7977de34ff348f5c74809027.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investopedia",
          "url": "https://www.investopedia.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investopedia.com/5-things-to-know-before-the-stock-market-opens-august-05-2025-11784826",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-things-know-stock-market-113622181.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PLTR"
            },
            {
              "symbol": "AMD"
            },
            {
              "symbol": "2330.TW"
            },
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "^SPX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T07:03:36+00:00",
    "headline": "Vertex Pharmaceuticals Inc (VRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
    "summary": "Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and successful product launches, while addressing challenges in market access and R&D investments.",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-inc-vrtx-q2-070336373.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "889a06c0-a4d8-3bd6-88a9-321d25a3bd68",
      "content": {
        "id": "889a06c0-a4d8-3bd6-88a9-321d25a3bd68",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals Inc (VRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...",
        "description": "",
        "summary": "Vertex Pharmaceuticals Inc (VRTX) reports a 12% revenue increase and successful product launches, while addressing challenges in market access and R&D investments.",
        "pubDate": "2025-08-05T07:03:36Z",
        "displayTime": "2025-08-05T07:03:36Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/38abcc9dbc5b26366306a2d085a6a7da",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7HBd0POp7X0FHdAjuJZSjg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/38abcc9dbc5b26366306a2d085a6a7da.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vTyI6qFX1SKD5XAV_fqEJQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/38abcc9dbc5b26366306a2d085a6a7da.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-inc-vrtx-q2-070336373.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-inc-vrtx-q2-070336373.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-08-05T06:31:00+00:00",
    "headline": "Vertex plan to build on pain drug breakthrough hits hurdles",
    "summary": "The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain would take more testing. A successor medicine, meanwhile, fell short in Phase 2.",
    "url": "https://www.biopharmadive.com/news/vertex-pain-neuropathic-delay-vx-993-negative-trial/756753/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "069bdc8f-84ca-3330-8be1-c833a4f02711",
      "content": {
        "id": "069bdc8f-84ca-3330-8be1-c833a4f02711",
        "contentType": "STORY",
        "title": "Vertex plan to build on pain drug breakthrough hits hurdles",
        "description": "",
        "summary": "The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain would take more testing. A successor medicine, meanwhile, fell short in Phase 2.",
        "pubDate": "2025-08-05T06:31:00Z",
        "displayTime": "2025-08-05T06:31:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/1ce8dafda941972e9c7c338ace2dc357",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LGbrlb9.HJde2s_DdFclLA--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/1ce8dafda941972e9c7c338ace2dc357.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/VZgRCozwAKxvDrUaifq1Gw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/1ce8dafda941972e9c7c338ace2dc357.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/vertex-pain-neuropathic-delay-vx-993-negative-trial/756753/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-plan-build-pain-drug-063100333.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]